Provider of drug discovery and development platform. The platform utilizes AI technology to predict and identify drug candidate molecules for therapeutic purposes. The company was founded in 2019 and headquartered in Paris, France. It has raised $10.6M in series a funding, with backing from Debiopharm, Omnes Capital, Y Combinator, EIT Health. The company operates in the HealthTech - Life Sciences Tech, Life Sciences - Life Sciences Tech, Life Sciences - Genomics space. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers. With a focus on innovation and market differentiation, the company continues to expand its product offerings and strengthen its competitive position.
WhiteLab Genomics
Series AProvider of drug discovery and development platform. The platform utilizes AI technology to predict and identify drug candidate molecules for therapeutic purposes. The company was founded in 2019 and headquartered in Paris, France. It has raised $10.6M in series a funding, with backing from Debiopharm, Omnes Capital, Y Combinator, EIT Health. The company operates in the HealthTech - Life Sciences Tech, Life Sciences…
About
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Genetic Engineering,
Genomics > Enabling Technologies > Technology Platforms > Genetic Engineering
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in HealthTech — full fund directory with check size and geography.